Digital PCR has the potential to supplant quantitative real-time PCR as the assay technology of choice for certain applications, particularly the detection and absolute quantification of low-level DNA targets in oncology and HIV research, industry stakeholders and early users sai
The first version of the sequencer, about to enter beta-testing, will cost around $250,000 and will be able to generate several gigabases of data in a 5.5-hour run with $250 in consumables costs per gigabase. That price is expected to fall to as little as $2 with later generations.
The web-based CollabRx One program, which will charge cancer patients between $50,000 and $100,000 to generate genetically-targeted treatment options, compares 15,000 genes against tumor samples to gauge how they respond to as many as 5,000 drugs.
The company last month presented data showing that the test could be used to detect cancer, but more work is needed to refine the test so that it can distinguish between different types of malignancies.
The data presented last week at the Molecular Medicine Tri-Conference showed that the investigational test detected "dramatically different" miRNA expression patterns in the blood of cancer patients compared to those who were cancer-free.